2023
May
Personalized PDAC vaccines have entered the clinic
May 31, 2023
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death, and while surgery can be curative, the vast majority of patients relapse and succumb to their disease, even when given additional chemotherapy. While PDAC is generally resistant to immune checkpoint inhibitors, recent studies have shown that they do often harbor immunogenic neoantigens...
Targeting NRP2-VEGF to overcome immunosuppression and chemotherapy resistance in aggressive cancers
May 24, 2023
Neuropilin-2 (NRP2) is a transmembrane protein that binds ligands such as vascular endothelial growth factor (VEGF). It is expressed in several tumor types, and overexpressed in aggressive, treatment-resistant tumors, such as triple-negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), and neuroendocrine prostate cancer (NEPC). Two recent papers from the same laboratory, published...
CIMT Annual Meeting 2023
May 17, 2023
The ACIR team attended the CIMT Annual Meeting 2023 in Mainz, Germany. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Tumor immune microenvironment and implications for immunotherapyGuoliang CuiRafi AhmedMiriam Merad Ira Mellman Judit Díaz-Gómez Naveen MehtaT cell therapies and bispecificsGeorge Coukos Kristen...
Tumor-reactive T cells engineered to not get exhausted after adoptive transfer
May 10, 2023
T cell exhaustion in response to chronic activation of effector CD8+ T cells limits the efficacy of particular adoptive cell transfer (ACT) therapies. Corria-Osora et al. hypothesized that T cells could be rewired by engineering them to express orthogonal cytokines to acquire and maintain a functional state upon chronic stimulation. The researchers assessed...
Targeting Tregs, but only in the tumor
May 3, 2023
Tregs are an attractive target in cancer immunotherapy, as they play a strong role in inhibiting antitumor immune responses. However, targeting Tregs can also disrupt the system of checks and balances that prevents harmful autoimmune responses. In search of strategies for targeting Tregs that infiltrate tumors (TI-Tregs) without disrupting Tregs in the periphery...
